CoChat

Aspiration risk with glucagon‐like peptide 1 ( GLP ‐1) agonists

Open access
Marroquin‐Harris, M., Olesnicky, B. · 2023 · Anaesthesia
Cited by 20

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

We would like to draw attention to a concerning issue regarding the use of glucagon-like peptide 1 (GLP-1) agonists, commonly prescribed for diabetes management and weight loss, and their potential impact on gastric emptying and the associated aspiration risk. The GLP-1 agonist is an incretin, a naturally occurring peptide primarily synthesised in intestinal endocrine cells located in the terminal ileum and proximal colon. Upon nutrient ingestion, GLP-1 is rapidly released, engaging cAMP-linked GLP-1 receptors in various target tissues, including the pancreas (stimulating insulin release), the hypothalamus (stimulating satiety centres) and gastric neuronal cells (delaying gastric emptying). While endogenous GLP-1 has a short half-life of 2–3 min, pharmacological GLP-1 agonist analogues with extended durations of action have been developed for the management of diabetes mellitus (e.g. semaglutide, duraglutide, liraglutide) and weight management (e.g. semaglutide, liraglutide). Emerging evidence indicates a significant delay in gastric emptying associated with GLP-1 agonist use [1]. Furthermore, individuals with diabetes commonly experience impaired gastric emptying, with approximately 30–50% of long-standing diabetic patients exhibiting abnormally slow gastric emptying. Tachyphylaxis to delayed gastric emptying may occur with rapidly acting GLP-1 agonists administered by intravenous infusion [2]. However, there is evidence to suggest that longer acting GLP-1 agonists may impair gastric emptying for at least 8 weeks [3]. Moreover, patients utilising GLP-1 agonists for weight management may adopt intermittent drug regimens, including periods of drug ‘holidays’ between treatments. Studies suggest that both acute and intermittent use of GLP-1 agonists result in comparable impairment of gastric emptying [4]. Of particular concern to anaesthetists is the potential risk of aspiration associated with delayed gastric emptying. Several published case reports have documented instances of aspiration in patients receiving GLP-1 agonists, emphasising the importance of considering this risk [5]. However, the clinical significance of delayed gastric emptying induced by GLP-1 agonists remains incompletely understood. Additionally, the duration of the drug's effect and the timing of gastric emptying restoration following drug cessation require further investigation. Consideration should be given to performing gastric ultrasound to determine residual gastric content before induction of anaesthesia in these patients. However, it is important to note that there is currently a lack of evidence supporting the use of gastric ultrasound in this specific context. Therefore, further research efforts are warranted to elucidate the clinical significance of these effects and provide guidance on appropriate management strategies for patients receiving GLP-1 agonists who require anaesthesia and surgery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/anae.16099

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Marroquin‐Harris, M., & Olesnicky, B.
Venue
Anaesthesia
Publisher
Wiley
Published
2023-07-13
Volume
78
Issue
12
Pages
1524-1524
ISSN
  • 0003-2409 (ISSN-L)
  • 1365-2044
OpenAlex
W4384277104
Cited by
20
References
4
FWCI
3.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.